Tesa/IPA Protocol
Begrenzte ForschungTesamorelin + Ipamorelin GH Secretagogue Blend
The Tesa/IPA blend combines two complementary growth hormone secretagogues: Tesamorelin (a GHRH analog that stimulates GH release from the pituitary) and Ipamorelin (a selective ghrelin mimetic/GHRP
Molekulare und Forschungsdaten
- Sequenz
- Tesamorelin (GHRH analog) + Ipamorelin (GHRP)
- Primäre Ziele
- ghrelin-receptor, ghrh-receptor
- Wege (Forschung)
- injectable
- Lagerung
- Reconstituted: 2-8°C, use within 4-6 weeks
Overview
The Tesa/IPA blend combines two complementary growth hormone secretagogues: Tesamorelin (a GHRH analog that stimulates GH release from the pituitary) and Ipamorelin (a selective ghrelin mimetic/GHRP that amplifies GH pulses). This combination addresses both the GHRH and GHRP pathways for synergistic GH release. Common formulations include 5mg/5mg (1:1 ratio) and 10mg/3mg (higher Tesamorelin) variants. Tesamorelin is FDA-approved for HIV-associated lipodystrophy, while Ipamorelin remains investigational.
Mechanism of action
The blend leverages two distinct GH-releasing pathways: Tesamorelin is a synthetic GHRH analog that directly stimulates growth hormone-releasing hormone receptors on pituitary somatotrophs, triggering GH synthesis and secretion in a pulsatile, physiological manner. Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist that amplifies GH pulses without significantly affecting cortisol or prolactin. Together, they produce synergistic GH release greater than either compound alone, while maintaining the body’s natural feedback mechanisms.
Key research findings
- Synergistic GH release from dual pathways
- More physiological pulsatile GH secretion
- Tesamorelin’s proven lipodystrophy benefits
- Ipamorelin’s clean side effect profile
- Does not significantly affect cortisol or prolactin
- Single injection convenience
- May improve body composition, sleep, and recovery
Research applications
Body Composition
- Fat Reduction — Tesamorelin has demonstrated fat reduction in clinical trials; synergy with Ipamorelin may enhance effects.
- Visceral Fat Loss — Tesamorelin specifically reduces visceral adipose tissue (FDA-approved indication).
- Lean Mass Support — Enhanced GH promotes protein synthesis and lean tissue preservation.
Recovery & Wellness
- Sleep Quality — GH secretagogues often improve deep sleep quality.
- Recovery Enhancement — Enhanced GH supports tissue repair and recovery from exercise.
- Anti-Aging Support — Restoring more youthful GH levels may provide anti-aging benefits.
Metabolic Health
- Lipid Profile — Tesamorelin has shown improvements in lipid parameters in studies.
- IGF-1 Optimization — Increased GH leads to increased IGF-1 production.
Tesa/IPA Protocol Häufig gestellte Fragen
Why combine tesamorelin and ipamorelin instead of using them separately?+
Tesamorelin and ipamorelin work on complementary GH-release pathways (GHRH vs GHRP receptors), producing synergistic GH release greater than either alone. The combination mimics natural pulsatile GH secretion more effectively while maintaining safety with less cortisol/prolactin elevation than GHRPs used solo.
What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?+
5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for athletic recovery; 10/3 for fat-loss focused protocols with body composition optimization goals.
Should the Tesa/IPA blend be taken on an empty stomach?+
Yes, both tesamorelin and ipamorelin work best on an empty stomach (2-3 hours before eating). Evening injection (before bed) on an empty stomach optimizes the protocol by aligning with natural nighttime GH pulses and avoiding food-induced metabolic interference.
Can Tesa/IPA be combined with CJC-1295 or other GH secretagogues?+
No, combining Tesa/IPA (which already contains both GHRH and GHRP pathways) with additional GHRPs or GHRH analogs risks excessive pituitary stimulation. The blend is specifically designed as a complete dual-pathway system that shouldn't require additional GH secretagogues.
References
- [1]Metabolic effects of a growth hormone-releasing factor in patients with HIVNew England Journal of Medicine
- [2]Ipamorelin, the first selective growth hormone secretagogueEuropean Journal of Endocrinology
- [3]GHRH + GHRP SynergyEndocrine Reviews
- [4]No Published Studies on Tesa/IPA CombinationN/A
- [5]Efficacy and safety of tesamorelin in people with HIV on integrase inhibitorsAIDS
- [6]Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal ObesityJAMA Network Open
- [7]Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin in HIV-associated lipodystrophy: A meta-analysisClinical Endocrinology
Verwandte Peptide
ACE-031
Emerging researchMyostatin Inhibitor | Experimental Muscle Growth
ACE-031 is a soluble form of the activin type IIB receptor (ActRIIB) fused to an IgG1 Fc domain.
CJC-1295
In clinical trialsLangwirkendes GHRH-Analog
CJC-1295 ist ein synthetisches Analog des Wachstumshormonfeinfrequenzlösungs-Hormons (GHRH), das für eine dramatisch verlängerte Halbwertzeit entwickelt wurde und auf seine Fähigkeit untersucht wird, Wachstumshormonspiegel und IGF-1-Spiegel zu erhöhen.
CJC-1295 with DAC
Well studiedLong-Acting Growth Hormone Releasing Hormone Analog | Extended Release
Modified growth hormone releasing hormone engineered for extended duration via albumin-binding technology. DAC binds to albumin, extending half-life and providing continuous GHRH receptor stimulation.
CJC/IPA Protocol
Well studiedGHRH/GHRP Combination | Growth Hormone Optimization
A dual-pathway protocol combining CJC-1295 and Ipamorelin that targets growth hormone secretion through complementary mechanisms.